MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating)’s stock price traded up 2.2% on Tuesday . The stock traded as high as $7.42 and last traded at $7.40. 10,909 shares changed hands during trading, a decline of 89% from the average session volume of 99,399 shares. The stock had previously closed at $7.24.
Analysts Set New Price Targets
Several equities analysts have weighed in on the company. Cowen initiated coverage on MoonLake Immunotherapeutics in a research note on Thursday, July 7th. They set an “outperform” rating on the stock. HC Wainwright initiated coverage on MoonLake Immunotherapeutics in a research report on Thursday, July 21st. They set a “buy” rating and a $28.00 target price for the company. Cowen initiated coverage on MoonLake Immunotherapeutics in a research report on Thursday, July 7th. They set an “outperform” rating for the company. Finally, SVB Leerink initiated coverage on MoonLake Immunotherapeutics in a research report on Thursday, August 25th. They set an “outperform” rating and a $17.00 target price for the company.
MoonLake Immunotherapeutics Price Performance
The business has a fifty day moving average price of $7.17.
Institutional Investors Weigh In On MoonLake Immunotherapeutics
MoonLake Immunotherapeutics Company Profile
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis.
- Get a free copy of the StockNews.com research report on MoonLake Immunotherapeutics (MLTX)
- Roku Stock is Down but Not Out
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- Has AMD stock stock fallen too far?
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.